Allurion Technologies (ALURW) Debt to Equity (2022 - 2024)

Allurion Technologies (ALURW) reported Debt to Equity of -$0.59 for Q1 2024, down 8.64% quarter-over-quarter from -$0.54 in Q4 2023.

Allurion Technologies (ALURW) Debt to Equity (2022 - 2024) Analysis & Trends

Allurion Technologies has reported Debt to Equity for 3 years, with the latest figure at -$0.59 in Q1 2024.

  • For the quarter ending Q1 2024, Debt to Equity changed N/A year-over-year to -$0.59; the trailing twelve-month figure through Mar 2024 stood at -$0.59 (changed N/A YoY), and the FY2023 full-year result was -$0.54, up 67.18% from the prior year.
  • Debt to Equity for Q1 2024 stood at -$0.59, down from -$0.54 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.54 in Q4 2023, with the low at -$1.65 in Q4 2022.
  • Historically, Debt to Equity has averaged -$0.93 across 3 years, with a median of -$0.75 in 2023.
  • The largest YoY upside for Debt to Equity was 67.18% in 2023 against a maximum downside of 67.18% in 2023.
  • Allurion Technologies' Debt to Equity stood at -$1.65 in 2022, then soared by 67.18% to -$0.54 in 2023, then slipped by 8.64% to -$0.59 in 2024.
  • The last three Debt to Equity figures came in at -$0.59 (Q1 2024), -$0.54 (Q4 2023), and -$1.09 (Q3 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 0.65
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 0.64
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 0.57
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 0.71
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 0.95
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 0.27
10 Allurion Technologies - - 1.23 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2024 -0.59
Dec 31, 2023 -0.54
Sep 30, 2023 -1.09
Jun 30, 2023 -0.75
Dec 31, 2022 -1.65